Potentiation of aspirin-induced cerebroprotection by minocycline: A therapeutic approach to attenuate exacerbation of transient focal cerebral ischaemia

Diabetes and Vascular Disease Research

Volumn 9, Issue 1, 2012, Pages 25-34

  Bhatt, Lokesh K ^a   Addepalli, Veeranjaneyulu ^b  

^a SVKM S DR BHANUBEN NANAVATI COLLEGE OF PHARMACY   (India)

^b Shri Vile Parle Kelavani Mandal's Narsee Monjee Institute of Management Studies   (India)

Author keywords

Diabetic complications; extracellular matrix; matrix metalloproteinase; transient focal cerebral ischaemia

Indexed keywords

ACETYLSALICYLIC ACID; COLLAGEN; CYCLOOXYGENASE 2; GELATIN; GELATINASE A; GELATINASE B; GLUCOSE; MINOCYCLINE; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BODY WEIGHT; BRAIN EDEMA; BRAIN INFARCTION SIZE; GLUCOSE BLOOD LEVEL; MALE; MIDDLE CEREBRAL ARTERY; MIDDLE CEREBRAL ARTERY OCCLUSION; MORTALITY; NONHUMAN; RAT; REPERFUSION INJURY; STREPTOZOCIN DIABETES; TRANSIENT ISCHEMIC ATTACK; ZYMOGRAPHY;

ANIMALS; ASPIRIN; BLOOD GLUCOSE; BLOOD-BRAIN BARRIER; BODY WEIGHT; BRAIN; BRAIN EDEMA; CAPILLARY PERMEABILITY; CEREBRAL INFARCTION; CYCLOOXYGENASE 2 INHIBITORS; CYTOPROTECTION; DIABETES COMPLICATIONS; DIABETES MELLITUS, EXPERIMENTAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ISCHEMIC ATTACK, TRANSIENT; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MINOCYCLINE; PROTEASE INHIBITORS; RATS; RATS, WISTAR; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 83455172609     PISSN: 14791641     EISSN: 17528984     Source Type: Journal    
DOI: 10.1177/1479164111427753     Document Type: Article

References (46)

1. Biller J, Love BB. Diabetes and stroke. Med Clin N Am. 1993 ; 77: 95-110 (Pubitemid 23066799)
2. Vinik A, Flemmer M. Diabetes and macrovascular disease. J Diabetes Comp. 2002 ; 16: 235-245 (Pubitemid 34553332)
3. Coccheri S. Approaches to prevention of cardiovascular complications and events in diabetes mellitus. Drugs. 2007 ; 67: 997-1026 (Pubitemid 46744476)
4. Hu J, Van den Steen PE, Sang QX, Opdenakke G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov. 2007 ; 6: 480-498 (Pubitemid 47064570)
5. Woessner JF, Nagase H Matrix metalloproteinases and TIMPs. 1 st edn.New York: Oxford University Press, 2000; pp. 87-97. New York: Oxford University Press ; 2000: 87-97.
6. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003 ; 92: 827-839 (Pubitemid 36542523)
7. Corbel M, Belleguic C, Boichot E, Lagente V. Involvement of gelatinases (MMP-2 and MMP-9) in the development of airway inflammation and pulmonary fibrosis. Cell Biol Toxicol. 2002 ; 18: 51-61 (Pubitemid 34269789)
8. John A, Tuszynski G. The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res. 2002 ; 7: 14-23
9. Fatar M, Stroick M, Griebe M, Hennerici M. Matrix metalloproteinases in cerebrovascular diseases. Cerebrovasc Dis. 2005 ; 20: 141-151 (Pubitemid 41254175)
10. Ammarguellat F, Larouche II, Schiffrin EL. Myocardial fibrosis in DOCA salt hypertensive rats: effect of endothelin ET(A) receptor antagonism. Circulation. 2001 ; 103: 319-324 (Pubitemid 32095422)
11. Galis ZS, Sukhova G, Lark M, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994 ; 94: 2494-2503
12. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002 ; 90: 251-262 (Pubitemid 34633925)
13. Kadoglou NP, Daskalopoulou SS, Perrea D, Liapis CD. Matrix metalloproteinases and diabetic vascular complications. Angiology. 2005 ; 56: 173-189 (Pubitemid 40404472)
14. Hao F, Yu JD. High glucose enhance expression of matrix metalloproteinase-2 in smooth muscle cells. Acta Pharmacol Sin. 2003 ; 24: 534-538
15. Bhatt LK, Veeranjaneyulu A. A therapeutic approach to treat cardiovascular dysfunction of diabetes. Exp Toxicol Pathol. 2011 ;:
16. Li PA, Shamloo M, Katsura K, Smith ML, Siesjo BK. Critical values for plasma glucose in aggravating ischemic brain damage: correlation to extracellular pH. Neurobiol Dis. 1995 ; 2: 97-108
17. Zea Longa E, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989 ; 20: 84-91 (Pubitemid 19040218)
18. Bergeron M, Yu AY, Solway KE, Semenza GL, Sharp FR. Induction of hypoxia-inducible factor-1 (HIF-1) and its target genes following focal ischaemia in rat brain. Eur J Neurosci. 1999 ; 11: 4159-4170 (Pubitemid 30009246)
19. Uyama O, Okamura N, Yanase M, Narita M, Kawabata K, Sugita M. Quantitative evaluation of vascular permeability in the gerbil brain after transient ischemia using Evans Blue fluorescence. J Cereb Blood Flow Met. 1998 ; 8: 282-284
20. Kamada H, Yu F, Nito C, Chan PH. Influence of hyperglycemia on oxidative stress and matrix metalloproteinase-9 activation after focal cerebral ischemia/reperfusion in rats: relation to blood-brain barrier dysfunction. Stroke. 2007 ; 38: 1044-1049 (Pubitemid 46568472)
21. Rosenberg GA. Matrix metalloproteinase in neuroinflammation. Glia. 2002 ; 39: 279-291
22. Lo EH, Dalkara T, Moskowitz MA. Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci. 2003 ; 4: 399-415 (Pubitemid 37280178)
23. Lo EH, Wang X, Cuzner ML. Extracellular proteolysis in brain injury and inflammation: role for plasminogen activators and matrix proteinases. J Neurosci Res. 2002 ; 69: 1-9 (Pubitemid 34734159)
24. Del Zoppo GJ, Mabuchi T. Cerebral microvessel responses to focal ischemia. J Cereb Blood Flow Metab. 2003 ; 23: 879-894 (Pubitemid 36959394)
25. Ammarguellat FZ, Gannon PO, Amiri F, Schiffrin EL. Fibrosis, matrix metalloproteinases, and inflammation in the heart of DOCA-salt hypertensive rats: role of ET(A) receptors. Hypertension. 2002 ; 39: 679-684 (Pubitemid 34165205)
26. Tsuji K, Aoki T, Tejima E, Arai K, Lee SR, Atochin DN, et al. Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia. Stroke. 2005 ; 36: 1954-1959 (Pubitemid 41266533)
27. Lapchack PA, Arujo DM, Pakola S, Song D, Wei J, Zivin JA. Microplasmin: a novel thrombolytic that improves behavioral outcome after embolic strokes in rabbits. Stroke. 2002 ; 33: 2279-2284 (Pubitemid 35014643)
28. Sumii T, Lo EH. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke. 2002 ; 33: 831-836 (Pubitemid 34204013)
29. Martin A, Komada MR, Sane DC. Abnormal angiogenesis in diabetes mellitus. Med Res Rev. 2003 ; 23: 117-145 (Pubitemid 36241095)
30. Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein HC. Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. Stroke. 2001 ; 32: 2426-2432 (Pubitemid 32954818)
31. Douketis J. Review: stress hyperglycemia after ischemic stroke indicates a greater risk for death in patients without diabetes. ACP J Club. 2002 ; 136: 114
32. Kagansky N, Levy S, Knobler H. The role of hyperglycemia in acute stroke. Arch Neurol. 2001 ; 58: 1209-1212 (Pubitemid 32751739)
33. Lehto S, Ronnemaa T, Pyorala K, Laakso M. Predictors of stroke in middle-aged patients with non-insulindependent diabetes. Stroke. 1996 ; 27: 63-68 (Pubitemid 26008297)
34. Pulsinelli W, Waldman S, Sigsbee B, Rawlinson D, Scherer P, Plum F. Experimental hyperglycemia and diabetes mellitus worsen stroke outcome. Trans Am Neurol Assoc. 1980 ; 105: 21-24
35. Pulsinelli WA, Levy DE, Sigsbee B, Scherer P, Plum F. Increased damage after ischemic stroke in patients with hyperglycemia with or without established diabetes mellitus. Am J Med. 1983 ; 74: 540-544 (Pubitemid 13125970)
36. Astrup J, Siesjo BK, Symon L. Thresholds in cerebral ischemia-the ischemic penumbra. Stroke. 1981 ; 12: 723-725 (Pubitemid 12227362)
37. Back T. Pathophysiology of the ischemic penumbra-revision of a concept. Cell Mol Neurobiol. 1998 ; 18: 621-638
38. Fisher M, Garcia JH. Evolving stroke and the ischemic penumbra. Neurology. 1996 ; 47: 884-888 (Pubitemid 26362018)
39. Garcia JH, Yoshida Y, Chen H, Li Y, Zhang ZG, Lian J, et al. Progression from ischemic injury to infarct following middle cerebral artery occlusion in the rat. Am J Pathol. 1993 ; 142: 623-635 (Pubitemid 23057474)
40. Li PA, Rasquinha I, He QP, Siesjo BK, Csiszar K, Boyd CD, et al. Hyperglycemia enhances DNA fragmentation after transient cerebral ischemia. J Cereb Blood Flow Metab. 2001 ; 21: 568-576 (Pubitemid 32422877)
41. Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest. 1998 ; 102: 783-791 (Pubitemid 28399611)
42. Wang GX, Li GR, Wang YD, Yang TS, Ouyang YB. Characterization of neuronal cell death in normal and diabetic rats following experimental focal cerebral ischemia. Life Sci. 2001 ; 69: 2801-2810
43. Greene DA, Stevens MJ, Obrosova I, Feldman EL. Glucose-induced oxidative stress and programmed cell death in diabetic neuropathy. Eur J Pharmacol. 1999 ; 375: 217-223 (Pubitemid 29317606)
44. Li ZG, Zhang W, Grunberger G, Sima AA. Hippocampal neuronal apoptosis in type 1 diabetes. Brain Res. 2002 ; 946: 221-231 (Pubitemid 34876334)
45. Li ZG, Zhang W, Sima AA. C-peptide prevents hippocampal apoptosis in type 1 diabetes. Int J Exp Diabetes Res. 2002 ; 3: 241-245 (Pubitemid 36104738)
46. Fishman RA. Brain oedema. N Engl J Med. 1975 ; 293: 706-711